Biopharmaceutical company Intra-Cellular Therapies Inc (Nasdaq:ITCI) on Tuesday announced positive topline results from a Phase 3 trial evaluating CAPLYTA (lumateperone) for the prevention of relapse in patients with schizophrenia.

The study demonstrated that lumateperone significantly delayed relapse compared to placebo. There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.

The treatment was generally safe and well-tolerated.

These positive results highlight the potential of CAPLYTA as a maintenance therapy for schizophrenia.